[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630940":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":20,"centralContacts":25,"locations":32,"responsibleParty":52,"collaborators":20,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":20,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":76,"overallStatus":35,"whyStopped":20,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Fondazione del Piemonte per l'Oncologia","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Prospective Biomarker Collection Cohort","EXPERIMENTAL","Participants with histologically confirmed colon or rectal cancer will undergo protocol-defined longitudinal collection of stool and saliva samples during the diagnostic and therapeutic pathway. At the sponsor center, FFPE tissue and blood\u002Fplasma samples may also be collected. Clinical data and diet\u002Flifestyle questionnaire data will be prospectively recorded",[13,14],"Other: Prospective Biological Sample Collection and Longitudinal Molecular Profiling","Other: Diet and Lifestyle Assessment",[16,21],{"type":6,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"Prospective Biological Sample Collection and Longitudinal Molecular Profiling","Protocol-defined collection of stool and saliva samples at diagnosis\u002Fbaseline, after neoadjuvant treatment when applicable, at surgery after bowel preparation, at the time of anastomotic leak when applicable, 30 days after surgery, at day 0 of chemotherapy when applicable, at the end of chemotherapy, and at recurrence. At the sponsor center, FFPE tissue and blood\u002Fplasma samples may also be collected. Molecular analyses include microbiome profiling, miRNA sequencing, and mutational profiling on FFPE tissue",[9],null,{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":20},"Diet and Lifestyle Assessment","Administration of the EPIC food frequency questionnaire and the WCRF diet\u002Flifestyle score at diagnosis and approximately 1 year later, with integration of BMI and physical activity data.",[9],[26],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Felice Borghi, MD","CONTACT","0119933580","+39","felice.borghi@ircc.it",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Unit of Surgical Oncology - Fondazione del Piemonte per l'Oncologia- IRCCS Istituto di Candiolo, Candiolo, Turin 10060","RECRUITING","Candiolo","Torino (TO)","10060","Italy","IT",{"type":42,"coordinates":43},"Point",[44,45],7.59812,44.95858,{"lat":45,"lon":44},[48],{"name":49,"role":28,"phone":50,"phoneExt":30,"email":51},"Manuela Robella, MD","0119933630","manuela.robella@ircc.it",{"type":53,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100630940","mimicc-study-in-patients-with-colorectal-cancer-100630940",false,"NCT07494201","MIMICC Study in Patients With Colorectal Cancer","Analysis of MicroRNA Expression and Microbiome Composition During the Diagnostic-Therapeutic Pathway of Patients With Colorectal Carcinoma","MIMICC","Inclusion Criteria:\n\n* Histologically confirmed colon or rectal cancer on endoscopic biopsy\n* Any T stage, any N stage, M0-M1, candidate for surgical intervention\n* Colon tumors with indication for surgical resection with curative intent, including right hemicolectomy, left hemicolectomy, transverse colon resection, colectomy, or total proctocolectomy\n* Rectal tumors with indication for upfront surgery or neoadjuvant chemoradiotherapy\n* Written informed consent signed before any study procedure\n* Age between 18 and 75 years\n\nExclusion Criteria:\n\n* Tis\u002FT1 lesions or lesions almost completely resected by endoscopic polypectomy\u002FEMR\u002FESD\n* Use of immunosuppressive or immunomodulatory drugs within the previous 6 months\n* Current or previous diagnosis of other solid or hematologic malignancies\n* Inability or refusal to provide informed consent\n* Inability or refusal to be followed at the study institution\u002Fnetwork","ALL","18 Years","75 Years",{"count":66,"type":67},2500,"ESTIMATED","INTERVENTIONAL",[70],"NA","This multicenter prospective interventional study will evaluate stool and saliva microRNA expression and microbiome composition in patients with histologically confirmed colon or rectal cancer during key phases of the diagnostic and therapeutic pathway. The study aims to confirm and refine molecular signatures associated with colorectal cancer, assess the diagnostic and prognostic potential of salivary biomarkers, and characterize dynamic molecular changes during treatment and follow-up",[73,74,75],"Colorectal Cancer","Colon Cancer","Rectal Cancers",[77,78,79,80,81,82,83,84],"microRNA","microbiome","stool biomarkers","saliva biomarkers","colorectal cancer","anastomotic leak","diet","recurrence","2026-03-20",{"date":87,"type":88},"2026-03-27","ACTUAL",{"date":90,"type":88},"2025-09-15",{"date":92,"type":67},"2028-06-30",{"name":5,"class":6},1]